Show simple item record

Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura.

dc.contributor.authorEskazan, AE
dc.contributor.authorElverdi, Tuğrul
dc.date.accessioned2021-03-04T13:10:21Z
dc.date.available2021-03-04T13:10:21Z
dc.identifier.citationElverdi T., Eskazan A., "Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura.", Drug design, development and therapy, cilt.13, ss.1251-1258, 2019
dc.identifier.issn1177-8881
dc.identifier.othervv_1032021
dc.identifier.otherav_7af93986-fab4-4962-8277-9662e0492a57
dc.identifier.urihttp://hdl.handle.net/20.500.12627/84214
dc.identifier.urihttps://doi.org/10.2147/dddt.s134470
dc.language.isoeng
dc.titleCaplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura.
dc.typeMakale
dc.relation.journalDrug design, development and therapy
dc.contributor.department, ,
dc.identifier.volume13
dc.identifier.startpage1251
dc.identifier.endpage1258
dc.contributor.firstauthorID1447402


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record